质子泵抑制剂可减少 HFE 血色病患者的采血需求：双盲随机安慰剂对照试验。

Proton Pump Inhibitors Decrease Phlebotomy Need in HFE Hemochromatosis: Double-Blind Randomized Placebo-Controlled Trial.

机构信息

Department of Gastroenterology-Hepatology and Metabolic Center, University Hospital Leuven, Belgium.

Department of Internal Medicine, Gastroenterology and Clinical Geriatrics, Zuyderland Medical Center, Heerlen, The Netherlands; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht UMC+, The Netherlands.

出版信息

Gastroenterology. 2017 Sep;153(3):678-680.e2. doi: 10.1053/j.gastro.2017.06.006. Epub 2017 Jun 15.

DOI:10.1053/j.gastro.2017.06.006

PMID:28624580

Abstract

Phlebotomy constitutes the established treatment for HFE-related hemochromatosis. Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebotomy in this population. We conducted a randomized controlled trial to prove this. Thirty p.C282Y homozygous patients were randomly allocated to PPI (pantoprazole 40 mg/day) or placebo for 12 months. Phlebotomies were performed when serum ferritin was > 100 μg/L. Phlebotomy need turned out to be significantly lower in patients taking PPI (P = .0052). PPI treatment significantly reduces the need for phlebotomies in p.C282Y homozygous patients. In view of the known long-term safety profile of PPI, they can be a valuable addition to standard therapy. Clinicaltrials.gov: NCT01524757.

摘要

放血疗法是治疗 HFE 相关性血色病的既定方法。回顾性研究表明质子泵抑制剂 (PPI) 可减少该人群对放血疗法的需求。我们进行了一项随机对照试验来证明这一点。将 30 名 C282Y 纯合子患者随机分配至 PPI（泮托拉唑 40mg/天）或安慰剂组，治疗 12 个月。当血清铁蛋白>100μg/L 时进行放血。结果表明，接受 PPI 治疗的患者放血需求显著降低（P=0.0052）。PPI 治疗可显著减少 C282Y 纯合子患者的放血需求。鉴于 PPI 已知的长期安全性，它们可以成为标准治疗的有价值的补充。Clinicaltrials.gov：NCT01524757。